There was no significant difference between the SOX2 and SOX9 expression in male and female patients in lymph node metastases (mean SOX2 scores: male patients: 14.93 ± 30.77, female patients: 11.17 ± 23.80, p = 0.643; mean SOX9 scores: male patients: 22.026 ± 32.65, female patients: 18.69 ± 29.10, p = 0.707). This evidence concerns the gene SOX9 and metastatic malignant neoplasm in the lymph nodes.